FindTrial
Sign In

Etanercept 50 mg

DRUG5 trials

Sponsors

Centocor, Inc., Innovaderm Research Inc., Pfizer, Sun Pharmaceutical Industries Limited

Conditions

Plaque PsoriasisPlaque-type PsoriasisPsoriasis

Phase 3

An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis
CompletedNCT00454584
Centocor, Inc.Psoriasis
Start: 2007-03-31End: 2009-01-31Updated: 2012-11-21
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
CompletedNCT01241591
PfizerPsoriasis
Start: 2010-11-30End: 2013-01-31Updated: 2018-12-26
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
CompletedNCT01729754
Sun Pharmaceutical Industries LimitedPlaque Psoriasis
Start: 2013-02-05End: 2021-10-26Updated: 2022-03-08
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
WithdrawnNCT01936688
Sun Pharmaceutical Industries LimitedPlaque-type Psoriasis
Start: 2013-09-30End: 2018-08-31Updated: 2022-02-24

Phase 4

Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments
CompletedNCT00967538
Innovaderm Research Inc.Psoriasis
Start: 2009-09-30End: 2014-07-31Updated: 2014-07-24

Related Papers

Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE 1 and reSURFACE 2
Dermatology and Therapy2026-03-16
Efficacy and safety of tildrakizumab in patients with early- vs. late-onset psoriasis
British Journal of Dermatology2025-05-133 citations
Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.
2024-05-025 citations
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
Therapeutic Advances in Musculoskeletal Disease2023-01-0119 citations
Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
Dermatology and Therapy2022-09-1312 citations
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: <i>post hoc</i> analysis of 5‐year data from <scp>reSURFACE</scp> 1 and <scp>reSURFACE</scp> 2
Journal of the European Academy of Dermatology and Venereology2022-04-2320 citations
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
2021-05-0462 citations
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).
2020-09-1922 citations
Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.
2020-08-2013 citations
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
2020-04-3017 citations
Exposure–response characterisation of tildrakizumab in chronic plaque psoriasis: Pooled analysis of 3 randomised controlled trials
British Journal of Clinical Pharmacology2020-03-127 citations
Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis
Journal of the European Academy of Dermatology and Venereology2020-01-1019 citations
Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
2019-08-017 citations
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
2019-07-18109 citations
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis
Journal of Dermatological Treatment2019-07-0313 citations
Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development Programs
Drug Safety2019-02-08114 citations
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
2017-06-06400 citations
Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
2016-06-0734 citations
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
2015-06-04297 citations
Health-Related QOL Improved with Tofacitinib in Patients with Psoriasis
MD Conference Express2014-11-01

1 more papers not shown